MedPath

Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer

Not Applicable
Terminated
Conditions
Endometrial Cancer
Uterine Cancer
Interventions
Other: P2x7 assay
Registration Number
NCT00471120
Lead Sponsor
Dick Domanik
Brief Summary

This study aims at developing an accurate, simple, and cost-effective method for screening and early detection of uterine cancers

Detailed Description

The present study aims at developing an accurate, simple and cost-effective method for screening and early detection of uterine cancers in women using novel inventions and biotechnology methods for collection and assay of uterine cells. Results of P2X7 assays using tissues obtained from women with known uterine cancer and from women with histologically normal endometrium will be compared. These data will also serve as basis for future studies to test the predictive value of the method in population-based studies.

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
20
Inclusion Criteria
  • women scheduled to undergo hysterectomy
  • ages 18 years and older
Exclusion Criteria
  • pregnant women
  • students or employees under the direct supervision on the investigators.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
P2x7 AssayP2x7 assayCompare assay results with biopsy
Primary Outcome Measures
NameTimeMethod
To determine the accuracy potential of the P2X7 (protein and mRNA levels) for the detection of uterine endometrial cancers in women.Upon review of the assays.
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (4)

University of Arkansas

🇺🇸

Little Rock, Arkansas, United States

University Hospital CASE Medical Center

🇺🇸

Cleveland, Ohio, United States

University of Texas

🇺🇸

Galveston, Texas, United States

Eastern Virginia Medical School

🇺🇸

Norfolk, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath